Now we see the death of Modified HyperCVAD
Today we see the rise of Ibrutinib-Rituxan in the firt setting of disease treatment
than only come Idelalisib
and may be HyperCVAD
and if you think of Bendamustine-Rituxan (after failure of Ibritinib), do not forget Maintenance therapy with Rituxan (rather than Interferon)
(as a note, in Europe R-CHOP/R-DHAP but is there a need?) (trying to be controversial here, am I successful?) CRBCM, we take things in strides!
BUT IN THIS DISEASE, BENDAMUSTIN -RITUXAN MAY BE BETTER THE R-CHOP!
*WATCH THE MIPI